CerSci Therapeutics Competitors and Similar CompaniesClear all

CerSci Therapeutics's competitors and similar companies include Novartis, Pfizer, Fina Biosolutions and Chengdu Push Bio-technology.

	CerSci Therapeutics CerSci Therapeutics is a biotechnology company focused on delivering a new generation of non-opioid medicines.	Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products.	Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.	Fina Biosolutions Fina Biosolutions is a research and development stage biotechnology company.	Chengdu Push Bio-technology Chengdu Push Bio-technology (成都普思生物科技股份有限公司) is a provider of separation and purification of natural medicines and pharmaceutical research services.
Founding Date	Founding Date 2015	Founding Date 1996	Founding Date 1849	Founding Date 2006	Founding Date 2005
Type	Type Subsidiary	Type Public	Type Public	Type Private	Type Private
Tags	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development oncology pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma
Locations	Locations Dallas, US HQ	Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more	Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Footscray, AU Mulgrave, AU Sydney, AU Wien, AT see more	Locations Rockville, US HQ	Locations Cheng Du Shi, CN HQ
Employees	Employees 7	Employees 75,883	Employees 81,0008% decrease	Employees 1011% increase	Employees N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $56.7b (FY, 2025)	Revenue (est.) $62.6b (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods $8.4b (FY, 2025)	Cost of goods $16.1b (FY, 2025)	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit $49.8b (FY, 2025)	Gross profit $46.5b (FY, 2025)	Gross profit N/A	Gross profit N/A
Net income	Net income N/A	Net income $14b (FY, 2025)	Net income $7.8b (FY, 2025)	Net income N/A	Net income N/A
Operating ⚠
Phase III Trials Products	Phase III Trials Products N/A	Phase III Trials Products 44 (FY, 2022)	Phase III Trials Products 32 (FY, 2024)	Phase III Trials Products N/A	Phase III Trials Products N/A
Registration Phase Products	Registration Phase Products N/A	Registration Phase Products 8 (FY, 2022)	Registration Phase Products 5 (FY, 2024)	Registration Phase Products N/A	Registration Phase Products N/A
Funding
Total funding raised	Total funding raised $ 5.7m	Total funding raised $ 6.5m	Total funding raised N/A	Total funding raised N/A	Total funding raised N/A